Cepheid Wins FDA Approval for Xpress Flu, Flu/RSV Tests

Feb 15, 2017

NEW YORK (GenomeWeb) – Cepheid's Xpert Xpress Flu and Xpert Xpress Flu/RSV tests have received clearance from the US Food and Drug Administration, the firm announced today.

The tests are the first in the firm's planned line of Xpress branded tests — faster versions of the firm's Xpert test cartridges enabling test times of 30 minutes or less.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Menu

Cepheid Wins FDA Approval for Xpress Flu, Flu/RSV Tests

To read the full story....

Breaking News

Prenetics, Oxford Suzhou Center for Advanced Research Expand MDx Collaboration

Amgen, NeoGenomics Partner to Expand Biomarker Testing Access in NSCLC

Women's Health Startup Adyn Raises $2.5M in Seed Funding

Top Five Articles on 360Dx Last Week: DiaSorin, Siemens Healthineers, Lucira, And More

LGC Biosearch Technologies Gets FDA Emergency Use Authorization for SARS-CoV-2 Test

Biden Administration Funds $1B for COVID-19 Testing in Indian Country

Featured White Papers

A New Generation of PCR: At-home Testing and Preparing for Emerging Strains of COVID-19

Put Your Money Where Your Mouth Is: Tracking and Attacking COVID-19 through State-Wide Saliva Surveillance

What's Popular?

LGC Biosearch Technologies Gets FDA Emergency Use Authorization for SARS-CoV-2 Test

With Luminex Acquisition, DiaSorin to Broaden MDx Portfolio, Expand US Presence

Labs Craft SARS-CoV-2 Variant Genotyping Assays for Screening, Surveillance

NIH Funds $33M in COVID-19 Testing Projects for Safe Return of Students, Staff to School

Scope Fluidics Gets CE Mark for Rapid MRSA MDx Panel

Sponsorships